Immuno-Oncology

Matthew Gubens, MD, discusses how far the field of NSCLC has come with molecular testing, the challenges still ahead, and what novel assays could be on the horizon.

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses an early-phase trial of nivolumab (Opdivo) plus ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Mark A. Socinski, MD, executive medical director of the Florida Hospital Cancer Institute, discusses potential improvements to immunotherapy regimens for patients with lung cancer.

Amit Singal, MD, discusses the recent successes in the hepatocellular carcinoma treatment landscape and the challenges that still remain.

Barbara Burtness, MD, discusses her presentation on the current and emerging role of immunotherapy for patients with head and neck cancer.

Stephen M. Ansell, MD, PhD, discusses emerging combinations being investigated in patients with mantle cell lymphoma, the possible role of immunotherapy, and challenges oncologists are still struggling with in this population.

Bruno Sangro, MD, PhD, head of Hepatology Unit, Internal Medicine Department, Clinica Universidad de Navarra, discusses the safety profile of nivolumab (Opdivo) in advanced hepatocellular carcinoma (HCC).

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses managing toxicities associated with immunotherapy for patients with head and neck cancer.

Edward B. Garon, MD discusses the challenges researchers are currently facing with immunotherapy in NSCLC and what the future likely holds for the pivotal agents.

David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the immune-related toxicities for patients receiving checkpoint inhibitors for treatment of their renal cell carcinoma.

Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.

R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma.